SENS - Senseonics Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.8599
-0.0177 (-2.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.8776
Open0.8755
Bid0.8620 x 900
Ask0.8639 x 1300
Day's Range0.8500 - 0.8902
52 Week Range0.8000 - 3.3700
Volume909,533
Avg. Volume1,499,022
Market Cap174.949M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.4790
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.95
  • Business Wire

    Senseonics Announces Equity Grants to Employees Under Inducement Plan

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the "Plan") in accordance with NYSE American Company Guide Section 711(a).

  • Is Senseonics Holdings, Inc. (SENS) Going to Burn These Hedge Funds?
    Insider Monkey

    Is Senseonics Holdings, Inc. (SENS) Going to Burn These Hedge Funds?

    The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

  • Senseonics Holdings, Inc. (NYSEMKT:SENS): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.

    Senseonics Holdings, Inc. (NYSEMKT:SENS): What Does Its Beta Value Mean For Your Portfolio?

    If you're interested in Senseonics Holdings, Inc. (NYSEMKT:SENS), then you might want to consider its beta (a measure...

  • Thomson Reuters StreetEvents

    Edited Transcript of SENS earnings conference call or presentation 12-Nov-19 9:30pm GMT

    Q3 2019 Senseonics Holdings Inc Earnings Call

  • Business Wire

    Senseonics Launches Eversense CGM System with Non-Adjunctive Claim in the U.S.

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced today that Eversense users who download the new Eversense® CGM mobile app can start dosing insulin based off of the readings from their Eversense System without the need to do a confirmatory blood glucose fingerstick measurement.

  • Business Wire

    Senseonics Publishes Positive Longitudinal Performance Over Multiple Sensor Insertions and Removal Cycles of the Eversense® CGM System

    Senseonics Holdings, Inc. a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring system for people with diabetes, announced the publication of an assessment of the performance of multiple sequential cycles of Eversense 90 and 180-day CGM System use in the peer reviewed scientific journal Diabetes Technology ...

  • Senseonics Holdings (SENS) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Senseonics Holdings (SENS) Reports Q3 Loss, Misses Revenue Estimates

    Senseonics (SENS) delivered earnings and revenue surprises of 0.00% and -30.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Senseonics Holdings, Inc. Reports Third Quarter 2019 Financial Results

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring system for people with diabetes, today reported financial results for the quarter ended September 30, 2019.

  • Business Wire

    Medicare Establishes National Payment Rate for Eversense® CGM System

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only FDA-approved, long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced today that the Centers for Medicare and Medicaid Services (CMS) finalized a national payment rate for Eversense that was recently published in the calendar year 2020 Physician Fee Schedule Final Rule. The Eversense CGM system will be the first CGM technology to be reimbursed through the Part B Medical Services benefit for Medicare beneficiaries and expands access to the latest innovation in continuous glucose monitoring.

  • Hedge Funds Are Dumping Senseonics Holdings, Inc. (SENS)
    Insider Monkey

    Hedge Funds Are Dumping Senseonics Holdings, Inc. (SENS)

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • Earnings Preview: Senseonics Holdings (SENS) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Senseonics Holdings (SENS) Q3 Earnings Expected to Decline

    Senseonics (SENS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    Senseonics Holdings, Inc. Schedules Third Quarter 2019 Earnings Release and Conference Call for November 12, 2019 at 4:30 p.m. Eastern Time

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its third quarter 2019 financial results after market close on Tuesday, November 12, 2019. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease.

  • Business Wire

    Senseonics Announces a Positive Coverage Decision for Eversense CGM From Humana

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Humana is now providing coverage for the Eversense CGM System and insertion procedure, effective October 22, 2019. Under the Humana coverage policy patients with both type 1 diabetes and type 2 diabetes that require insulin are eligible for coverage for Eversense.

  • Do Insiders Own Shares In Senseonics Holdings, Inc. (NYSEMKT:SENS)?
    Simply Wall St.

    Do Insiders Own Shares In Senseonics Holdings, Inc. (NYSEMKT:SENS)?

    If you want to know who really controls Senseonics Holdings, Inc. (NYSEMKT:SENS), then you'll have to look at the...

  • Business Wire

    Senseonics Announces a Positive Coverage Decision for Eversense CGM from Health Care Service Corporation - Blue Cross Blue Shield of Illinois, Montana, New Mexico, Oklahoma and Texas

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Health Care Service Corporation (HCSC) - Blue Cross Blue Shield is now providing coverage for the Eversense CGM System, effective October 15, 2019. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.

  • Business Wire

    Senseonics Announces Equity Grants To Employees Under Inducement Plan

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it has made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a). On October 1, 2019, Senseonics' Compensation Committee granted sixteen new non-executive employees non-qualified stock options to purchase an aggregate of 263,000 shares of the Company’s common stock as an inducement for such employees to join the Company.

  • Business Wire

    Senseonics Announces the Completion of US Patient Enrollment in the PROMISE 180-Day Sensor Clinical Study

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the completion of patient enrollment in the Eversense PROMISE 180-day sensor Clinical Study. The PROMISE Clinical Study is intended to evaluate the safety and efficacy of the Eversense CGM System in people with diabetes over a 180-day period for the pre-market application submission to the U.S. Food and Drug Administration.

  • Thomson Reuters StreetEvents

    Edited Transcript of SENS earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 Senseonics Holdings Inc Earnings Call

  • GuruFocus.com

    Senseonics Holdings Inc (SENS) President and CEO Timothy T Goodnow Bought $97,350 of Shares

    President and CEO of Senseonics Holdings Inc (30-Year Financial, Insider Trades) Timothy T Goodnow (insider trades) bought 88,500 shares of SENS on 09/09/2019 at an average price of $1.1 a share. Continue reading...

  • If You Had Bought Senseonics Holdings (NYSEMKT:SENS) Stock A Year Ago, You'd Be Sitting On A 76% Loss, Today
    Simply Wall St.

    If You Had Bought Senseonics Holdings (NYSEMKT:SENS) Stock A Year Ago, You'd Be Sitting On A 76% Loss, Today

    It's not a secret that every investor will make bad investments, from time to time. But serious investors should think...

  • Senseonics Holdings, Inc. (SENS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Senseonics Holdings, Inc. (SENS) Q2 2019 Earnings Call Transcript

    SENS earnings call for the period ending June 30, 2019.

  • Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

    Senseonics (SENS) delivered earnings and revenue surprises of -6.25% and 1.93%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?